文献速递流行病学与生物统计真实世界研究与卫生经济新药、器械与细胞基因治疗研发

SGLT2抑制剂与急性肾损伤及肾脏不良事件:系统综述与Meta分析

Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2019-12-09

结果显示SGLT2抑制剂使急性肾损伤(AKI)风险降低36%(OR 0.64),但低血容量相关不良事件更常见(OR 1.20)。

要点

  • SGLT2抑制剂降低急性肾损伤风险(OR 0.64,95%CI 0.53-0.78)。
  • 低血容量相关不良事件在SGLT2抑制剂组更常见(OR 1.20)。
  • 恩格列净、达格列净和卡格列净对严重及任何不良事件的获益相似。

核心结论

  • SGLT2抑制剂在随机试验和真实世界研究中均降低急性肾损伤风险,尽管低血容量相关不良事件报告更多。

主要发现

  • 30项试验报告410例因AKI的严重不良事件,SGLT2抑制剂使AKI风险降低36%(OR 0.64 [95%CI 0.53-0.78],p<0.001)。
  • 41项试验报告1,089例任何严重程度的AKI事件(OR 0.75 [95%CI 0.66-0.84],p<0.001)。
  • 低血容量相关不良事件在SGLT2抑制剂组更常见(OR 1.20 [95%CI 1.10-1.31],p<0.001)。
  • 观察性研究中报告777例AKI事件,SGLT2抑制剂组AKI风险降低(OR 0.40 [95%CI 0.33-0.48],p<0.001)。

关键数值与推荐

  • 随机试验中SGLT2抑制剂降低AKI的OR为0.64(95%CI 0.53-0.78)。
  • 任何严重程度AKI事件的OR为0.75(95%CI 0.66-0.84)。
  • 低血容量相关不良事件的OR为1.20(95%CI 1.10-1.31)。
  • 观察性研究中AKI的OR为0.40(95%CI 0.33-0.48)。

临床怎么用

  • SGLT2抑制剂可降低2型糖尿病患者急性肾损伤风险,但需警惕低血容量相关不良事件。

局限性

  • 依赖非裁定安全性终点。
  • 研究间纳入标准和基线降糖治疗存在差异。
  • 肾脏不良事件和低血容量定义不一致。
  • 随访时间不同。
  • 缺乏AKI严重程度(I-III期)信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a positive effect on the progression of chronic kidney disease, but there is a concern that they might cause acute kidney injury (AKI). METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of the effect of SGLT2is on renal adverse events (AEs) in randomized controlled trials and controlled observational studies. PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov were searched without date restriction until 27 September 2019. Data extraction was performed using a standardized data form, and any discrepancies were resolved by consensus. One hundred and twelve randomized trials (n = 96,722) and 4 observational studies with 5 cohorts (n = 83,934) with a minimum follow-up of 12 weeks that provided information on at least 1 adverse renal outcome (AKI, combined renal AE, or hypovolemia-related events) were included. In 30 trials, 410 serious AEs due to AKI were reported. SGLT2is reduced the odds of suffering AKI by 36% (odds ratio [OR] 0.64 [95% confidence interval (CI) 0.53-0.78], p < 0.001). A total of 1,089 AKI events of any severity (AEs and serious AEs [SAEs]) were published in 41 trials (OR 0.75 [95% CI 0.66-0.84], p < 0.001). Empagliflozin, dapagliflozin, and canagliflozin had a comparable benefit on the SAE and AE rate. AEs related to hypovolemia were more commonly reported in SGLT2i-treated patients (OR 1.20 [95% CI 1.10-1.31], p < 0.001). In the observational studies, 777 AKI events were reported. The odds of suffering AKI were reduced in patients receiving SGLT2is (OR 0.40 [95% CI 0.33-0.48], p < 0.001). Limitations of this study are the reliance on nonadjudicated safety endpoints, discrepant inclusion criteria and baseline hypoglycemic therapy between studies, inconsistent definitions of renal AEs and hypovolemia, varying follow-up times in different studies, and a lack of information on the severity of AKI (stages I-III). CONCLUSIONS: SGLT2is reduced the odds of suffering AKI with and without hospitalization in randomized trials and the real-world setting, despite the fact that more AEs related to hypovolemia are reported.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med. 2019. PMID: 31815931. doi:10.1371/journal.pmed.1002983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。